VivoSim Labs Inc. (VIVS)
NasdaqCM: VIVS
· Real-Time Price · USD
0.32
+0.00 (0.00%)
At close: Aug 17, 2026, 3:57 PM
VivoSim Labs Inc. (VIVS) Stock Price, Analysis & Data
0.00% (1D)
| Bid | n/a |
| Market Cap | 4.26M |
| Revenue (ttm) | 112K |
| Net Income (ttm) | -12.34M |
| Beta | n/a |
| EPS (ttm) | -5.31 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 0.19 |
| P/S (ttm) | 38.02 |
| Earnings Date | n/a |
| Ask | n/a |
| Volume | 1,020,877 |
| Avg. Volume (20D) | 5,666,580 |
| Open | 0.32 |
| Previous Close | 0.32 |
| Day's Range | 0.31 - 0.33 |
| 52-Week Range | 0.31 - 5.30 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VIVS
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal si...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 14, 2012
Employees 9
Stock Exchange NasdaqCM
Ticker Symbol VIVS
Website https://vivosim.ai
Financial Performance
In 2026, VivoSim Labs's revenue was 131K, a decrease of -9.03% compared to the previous year's 144K. Earnings were -13.84M, an increase of 456.39%.
Financial StatementsEarnings Surprise
VivoSim Labs has released their quarterly earnings on Feb 19, 2025:
6 months ago · GuruFocus.com
NIO January Deliveries Nearly Double Year On YearEV maker opens 2026 with strong momentum
6 months ago · Associated Press Finance
BC-Most Active StocksGCL Global Holdings Ltd. 49,480,730 1.29
Page 1 of 2